Project Grant R43HL184690
Award Date 9/1/26
Completion Date 8/31/27
Dollars Obligated $595K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Irvine, CA 92606, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded The Children's Hospital Corporation (Boston Children's Hospital) $673,345 on June 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct THRIVE, a mechanistic analysis of transfusion and hemolysis-related injury in pediatric extracorporeal membrane oxygenation (ECMO). The award funds analysis of data from the TITRE multicenter trial, which enrolled over 220 children on ECMO and collected time-resolved plasma...
- Federal Project Grant Award Summary Perfusion Solutions Inc. received a $320,838 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective September 5, 2025, with completion targeted for February 28, 2027. The award supports Phase I development of a fail-safe, high-output cavopulmonary assist pump designed for pediatric and congenital heart disease patients with single ventricle physiology...
- The National Heart, Lung, and Blood Institute awarded Corvion, Inc. $2,999,968 on August 10, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a novel pediatric left ventricular assist device (P-LVAD) enabling children with end-stage heart failure to discharge home while awaiting heart transplantation or living long-term with the device. This is a Project Grant (SBIR Phase II). Corvion will engineer an implantable, ultra-low-power blood pump combining hydrodynamic...
- The National Heart, Lung, and Blood Institute awarded The Washington University $759,584 on September 1, 2026, for research developing high-density diffuse optical tomography (HD-DOT) methods for bedside neuroimaging of brain health in children undergoing extracorporeal membrane oxygenation (ECMO) support. This award is made under the Cardiovascular Diseases Research program (CFDA 93.837). The research aims to advance HD-DOT imaging to evaluate functional connectivity and cerebral oxygenation in...
- The National Heart, Lung, and Blood Institute awarded the University of Pittsburgh $773,237 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to examine the adoption, effectiveness, and system-level implications of veno-venous extracorporeal membrane oxygenation (ECMO) for treatment of severe acute respiratory failure. The research combines all-payer utilization data and private payer claims data to characterize ECMO adoption across U.S. hospitals, identify...
- The National Heart, Lung, and Blood Institute awarded the Regents of the University of Michigan $903,185 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837, Project Grant R01HL183614) to develop a Preemie ECMO System addressing respiratory failure in premature infants for whom extracorporeal membrane oxygenation is currently contraindicated. Work is performed at the University of Michigan in Ann Arbor, Michigan, with a period of performance through April 30,...
- The National Heart, Lung, and Blood Institute awarded Autonomous Healthcare Inc. $305,999 on September 1, 2026, under the Small Business Innovation Research (SBIR) program to conduct a Phase I feasibility study of E-Fusion, a bedside clinical decision support system designed to assist anesthesiologists, anesthetists, and critical care nurses with vasopressor titration and blood pressure management during surgery and in the intensive care unit. The system monitors mean arterial pressure (MAP) and...
- The National Heart, Lung, and Blood Institute awarded $316,609 to Remplenish, Inc. on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a novel myofunctional nipple device for preventing obstructive sleep apnea in infants. The recipient will design and validate a low-risk, low-burden device that delivers myofunctional therapy—oropharyngeal exercises integrated into infant bottle feeding—as a non-invasive first-line treatment and preventive measure...
- The National Heart, Lung, and Blood Institute awarded Perfusion Solutions Inc. $217,013 on August 1, 2026, to develop a bearingless, fail-safe pump for patients with single ventricle physiology following Fontan surgical palliation under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds Phase I research to design and develop a bearingless motor integrated into a centrifugal pump rotor, with the pump's stator incorporating the motor stator. The device is engineered to...
- The National Institute of Biomedical Imaging and Bioengineering awarded Colorado State University $231,000 on September 1, 2026, under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) to optimize hemocompatible extracorporeal membrane oxygenation (ECMO) membranes through biomimetic surface modification and computational fluid dynamics. The research addresses blood clotting and platelet loss in hollow fiber membrane oxygenators used in...